Targeted protein degradation is changing the landscape of cancer treatment – The ICR
The Institute of Cancer Research shared a post on LinkedIn:
“Targeted protein degradation is changing the landscape of cancer treatment. Rather than just inhibiting problematic cancer-driving proteins, the ICR is currently finding ways to remove them altogether.
In July 2024, we welcomed Dr Agnieszka Konopacka as Group Leader of the Induced Proximity Therapeutics group, which sits within the ICR Centre for Protein Degradation in the Division of Cancer Therapeutics.
Her team focuses on targeted protein degradation, an innovative technology that hijacks the cell’s waste disposal system to remove cancer-driving proteins, offering a novel way to treat cancer.
In our latest blog, Dr Konopacka shares how her recently established team is pushing boundaries with exciting new therapies such as PROTACs and molecular glues, which could overcome drug resistance and deliver more effective treatments to patients.
Read how the ICR is opening up new possibilities for cancer patients.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023